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Objective. Outcome measures for pulmonary arterial hypertension associated with systemic sclerosis (PAH-SSc) are
only partially validated. The aim of the present study was to establish an expert consensus regarding which outcome
measures are most appropriate for clinical trials in PAH-SSc.
Methods. Sixty-nine PAH-SSc experts (rheumatologists, cardiologists, pulmonologists) rated a list of disease domains
and measurement tools in an Internet-based 3-stage Delphi consensus study. In stages 2 and 3, the medians of domains
and measurement tools and frequency distributions of ratings, along with requests for re-ratings, were distributed to
respondents to provide feedback. A final score of items was identified by means of cluster analysis.
Results. The experts judged the following domains and tools as most appropriate for randomized controlled trials in
PAH-SSc: lung vascular/pulmonary arterial pressure and cardiac function both measured by right heart catheterization
and echocardiography, exercise testing measured by 6-minute walking test and oxygen saturation at exercise, severity of
dyspnea measured on a visual analog scale, discontinuation of treatment measured by (serious) adverse events, quality
of life/activities of daily living measured by the Short Form 36 and Health Assessment Questionnaire disability index, and
global state assessed by physician measured by survival.
Conclusion. Among experts in PAH-SSc, a core set of outcome measures has been defined for clinical trials by Delphi
consensus methods. Although these outcome measures are recommended by this expert group to be used as an interim
tool, it will be necessary to formally validate the present measures, as well as potential research measures, in further
studies.
INTRODUCTION
Pulmonary arterial hypertension (PAH), defined as a mean
pulmonary artery pressure 25 mm Hg at rest or 30 mm
Hg during exercise with a pulmonary capillary wedge
pressure 15 mm Hg by right heart catheterization, occurs
in approximately 8–12% of patients with systemic sclero-
sis (SSc) (1). It often takes a rapid and devastating course,
with right heart overload associated with exercise intoler-
ance, dyspnea, and arrhythmias (2). Survival in untreated
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SSc patients with PAH is even worse than in patients with
idiopathic PAH. Older studies have demonstrated a me-
dian survival of only 12 months in symptomatic patients,
and the risk of death was increased 3-fold (3,4). However,
the prognosis has considerably improved in the last de-
cade as new drugs from various classes have been intro-
duced to treat PAH related to SSc (PAH-SSc) (5,6). The
prostaglandin derivatives epoprostenol (7), treprostinil (8),
beraprost (9,10), and iloprost (11); the endothelin receptor
antagonists bosentan (12,13) and sitaxsentan (14,15); and
the phosphodiesterase V inhibitor sildenafil (16) have
been approved by some regulatory authorities on the basis
of randomized controlled trials.
Despite these therapeutic advances, outcome measures
required for the design of these trials are sometimes poorly
defined and are often poorly validated in PAH-SSc. In a
workshop on end points in PAH trials from the Third
World Symposium on Pulmonary Hypertension in 2003,
experts concluded that none of the end points currently
used in PAH trials is optimal (17,18). For example, al-
though the 6-minute walk test is the most widely used
primary end point and the only measure of exercise testing
accepted by the Food and Drug Administration, it is not
validated for patients with PAH with less severe disease
(New York Heart Association [NYHA]/World Health Orga-
nization [WHO] functional class I/II) (17).
In PAH-SSc, the validation of possible study end points
is even less convincing than in PAH in general. Although
patients with PAH-SSc have been included in many recent
trials, this group of patients has been somewhat underrep-
resented. Available data suggest that many outcome mea-
sures in PAH-SSc are less useful in comparison with out-
come measures in idiopathic PAH, including exercise
testing, survival, and time to clinical worsening (19). The
question arises as to the appropriateness of the available
core set of outcome measures including their sensitivity to
change in a disorder as complex and heterogeneous as SSc.
Outcome measures in PAH-SSc have to take into account
SSc-specific confounding factors such as musculoskeletal
problems, joint contractures, skin disease, fatigue, and de-
conditioning, which may affect cardiopulmonary testing.
In a systematic review performed at the Outcome Mea-
sures in Rheumatology Clinical Trials VI (OMERACT VI)
workshop on Outcome Measure Development for Clinical
Trials in SSc, a variety of end points used in clinical trials
were assessed according to the criteria of the OMERACT
filter of truth (face, content, construct, and criterion valid-
ity), discrimination (reliability/reproducibility and sensi-
tivity to change), and feasibility (20,21). The only PAH end
point that passed this filter was right heart catheterization
(the gold standard), and this was therefore judged to be
“ready for use in clinical trials in SSc patients” (19). How-
ever, right heart catheterization is invasive and therefore
often not feasible for repeated measures and for routine
followup. All other typically used end points such as
exercise tests, dyspnea indices, or noninvasive hemody-
namics (2-dimensional echocardiography) were not vali-
dated in 1 or more filter categories and therefore not rec-
ommended for trials. This clearly shows the need for a
structured approach to define clinical noninvasive end
points for PAH-SSc that take into account the method-
ologic problems associated with possible SSc-specific con-
founding factors (22).
One of the challenges with outcome measures is that
many potential candidates are discussed and available. It
is not feasible to validate all of them; thus, as a first step,
the most promising and most important measures need to
be selected. The aim of the present exercise was to estab-
lish an expert consensus regarding which outcome mea-
sures are appropriate to assess the various aspects of PAH-
SSc in clinical trials. A Delphi exercise among experts in
the treatment of PAH-SSc was performed to identify the
most appropriate and comprehensive measures to use in
randomized controlled trials in PAH-SSc. These selected
outcome measures then received priority for validation in
forthcoming studies.
MATERIALS AND METHODS
Study participants. A panel of 12 experts (Expert Panel
on Outcomes measures in PAH related to Systemic Scle-
rosis [EPOSS]; authors of this article) represented the
study steering committee. This interdisciplinary panel met
in November 2005 to define the aims, scope, and method-
ology of this study. In the next step, appropriate experts
were identified and invited to participate in the Delphi
exercise. To support the content validity of the process,
these experts (rheumatologists, cardiologists, and pulmo-
nologists) had to have several years of experience in the
diagnosis and treatment of PAH, had published articles on
PAH in peer-reviewed journals or had presented at major
meetings, were study investigators in multicenter end
point studies of PAH-SSc, and/or were members of con-
sensus committees. Members of the following groups were
invited: EPOSS group, Scleroderma Clinical Trials Consor-
tium, investigators of the Endothelin Antagonist Trial in
Mildly Symptomatic PAH Patients (EARLY) study or the
Bosentan and Sildenafil Versus Sildenafil Monotherapy
(COMPASS) PAH study, and PAH experts in the US (those
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with the highest numbers of patients with PAH-SSc, ac-
cording to the PHA Association Web site). Several experts
were members of 2 of the mentioned groups. All experts
(n  200) were invited by e-mail and informed about the
aims and scope of the Delphi study.
Delphi method. The Delphi method is a consensus
method for medical and health service research (23,24).
Such methods attempt to assess the extent of agreement
(consensus measurement) and to resolve disagreement
(consensus development). As opposed to the nominal
group technique (expert panel) and to a consensus devel-
opment conference, a Delphi exercise enables the partici-
pation of experts without geographic limitations (25,26).
In the Delphi procedure, participants can offer their opin-
ions independently and confidentially without the pres-
sures of face-to-face meetings. Thus, many group dynamic
problems are bypassed. In addition, participants can
change their opinion in consecutive stages of the process,
based on the systematic feedback from the results of the
previous rounds.
Three-stage Delphi survey. The Delphi exercise was In-
ternet based and was completed between January and No-
vember 2006. Although Web-based and conventional Del-
phi processes have not been formally compared, Internet-
based Delphi exercises have been shown to be feasible,
cost and time saving, and better accepted by users than
traditional paper-based Delphi methods (27). To ensure
security and confidentiality, each participant received a
personal log-on code with the e-mail invitation, allowing
individual access to the questionnaire on a Web page
specifically designed and programmed for the present Del-
phi study. The questionnaire was completed online by the
participants. Participants included members of the steer-
ing committee, who had no access to the primary data
while responding to the questionnaires in each round. It
was possible to interrupt the survey at any time and com-
plete it later. The survey was pilot tested among members
of the EPOSS steering committee and external experts. At
the end of each round of the survey, participants could
print an overview of their results for the records.
For the first stage of the 3-stage Delphi exercise, the
EPOSS steering committee performed a nonsystematic lit-
erature search. The results of this literature search were
discussed at the first meeting of the steering committee.
Based on this discussion, a list of 17 domains and 86 tools
was set up for the first stage of the Delphi exercise to define
outcome measures for a clinical trial in PAH-SSc (Figure
1). Domains were defined as a grouping of highly related
features that describe an organ, disease, function, or phys-
iology (e.g., cardiac function, pulmonary function, and
quality of life) and tools were defined as specific measures
that help to define a domain (e.g., right heart catheteriza-
tion, pulmonary function tests, health assessment ques-
tionnaires, respectively).
The respondent group was asked to score each domain
and tool on the survey for use as outcome measures in
randomized controlled trials of PAH-SSc. A 5-point scale,
where a score of 1 indicated “not important/appropriate at
all” and 5 indicated “very important/appropriate,” was
used for scoring. The duration of the randomized con-
trolled trial was not determined. In addition, participants
were asked whether they were actually using the tool (tick
box: “I use this”). Participants did not have to provide a
ranking of each individual domain or tool to be able to
finish the survey (e.g., if they were not familiar with all
specific tools). In the invitation e-mail and the online
introduction of the survey, it was highlighted that the
initially proposed domains and tools were only sugges-
tions, and additional proposals of tools and domains were
specifically requested. A text box of unlimited size was
provided for free text below each domain and its associ-
ated measurement tools to add new tools. Additional do-
mains could be proposed at the end of the questionnaire.
In stage 2 of the Delphi survey, participants were asked
to repeat the rating of the domains and tools based on the
information from the group rating of stage 1 (Figure 1).
This step in Delphi surveys is performed to give respond-
ers the chance to reflect their opinion on specific domains
and tools of the previous stage. The domains and tools
from stage 1 and all newly proposed tools were shown.
Results of the ratings from stage 1 were summarized as
medians for the individual domains and measurement
tools. For each domain and tool, participants were shown
their own rating in the previous stage as well as the me-
dian ratings of the entire group.
Before stage 3 of the Delphi survey (Figure 1), the num-
ber of domains and tools was reduced according to a
cluster analysis based on the ratings of stage 2 as outlined
Figure 1. Flowchart of the Delphi survey showing the number of
participants and the number of tools and domains from stage 1–3.
* Selected experts from the Expert Panel on Outcomes measures
in PAH related to Systemic Sclerosis (EPOSS) group, Scleroderma
Clinical Trials Consortium, pulmonary arterial hypertension
(PAH) study investigators (Endothelin Antagonist Trial in Mildly
Symptomatic PAH Patients, Bosentan and Sildenafil Versus Sil-
denafil Monotherapy PAH studies), and PAH experts in the US
(for details, see the Materials and Methods section).
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below. All domains and tools in the upper cluster repre-
sented domains and tools that were considered as impor-
tant in the previous stages. Participants were asked to
perform another, and final, rating of these items (stage 3 of
the Delphi survey). As in stage 2, participants were shown
their own rating in the previous stage as well as the me-
dian ratings of the entire group. When data from stage 3
were returned, a repeat cluster analysis was performed to
further reduce the number of domains and tools to make
them more practical for clinical trials.
Data management and entry. Data were directly en-
tered by participants via a hypertext preprocessor–based
Web surface into a structured query language (MySQL;
Microsystems, Santa Clara, CA) database and later trans-
ferred to SPSS 12.0 (SPSS, Chicago, IL) for the present
Delphi survey analysis. Data were backed up on a daily
basis. Descriptive statistics (medians, cumulative distribu-
tions) were performed. Newly proposed domains and tools
from stage 1 were reviewed and categorized by members of
the steering committee (OD, DEF, and LJR). During this
review, newly suggested tools/domains, which were the
same as already-existing tools, were merged. All other
newly proposed tools/domains were added to the list and
proceeded to stage 2. Spelling errors were corrected.
Statistical analysis. As noted above, a cluster analysis
(28) was performed by the biostatistician of the steering
committee (DH) on the items from stages 2 and 3 to differ-
entiate important/appropriate from unimportant/inappro-
priate domains and tools. This reduced the number of
domains and tools in a statistically significant manner.
Cluster analysis is an analysis of patterns in data by math-
ematical principles. It attempts to group domains in the
first instance and measurement tools in the second in-
stance. In the 2-step cluster analysis (29) performed in the
present study, the number of clusters was not predeter-
mined, but was generated by the automatic cluster algo-
rithm using Bayes information criterion. Patterns were
defined by a categorical structure (scored 1–5) and the
frequency distribution of that categorical structure based
on a log-likelihood distance measure. All domains and
tools were included in the cluster analysis including
newly proposed tools/domains from stage 1. The cluster
analysis of the domains and tools led to 2 clusters, with the
upper cluster representing the more important and the
lower cluster representing the less important domains and
tools. Domains and tools in the lower clusters were re-
moved from further evaluation.
Because cluster analysis does not allow missing values,
missing data were substituted using the median for the
domain or tool, respectively. For example, 10 respondents
did not rate the domain fatigue; these 10 missing values
were replaced with the median rating for fatigue (median;
3) calculated from the 65 nonmissing ratings. To avoid bias
by participants who would rather represent median ratings
than their own opinion, participants who completed fewer
than half of the required ratings were removed from the
analysis. In stage 2, this reduced the total number of re-
spondents from 75 to 69 for the domains and from 75 to 74
for the tools.
After the mathematical analysis was completed, the
steering committee carefully examined the data. If medi-
cally feasible, tools from the upper cluster belonging to a
domain in the lower cluster were reassigned to remaining
upper cluster domains. When tools in the upper cluster
belonging to a domain in the lower cluster could not be
reasonably assigned to another domain, the respective do-
main (even though in the lower cluster) was not removed
from further evaluation. Similarly, if a domain in the up-
per cluster did not contain any tool after the cluster ana-
lysis, the respective tools assigned to the specific domain
were not removed from further evaluation (even if the
tools had to be taken from among lower cluster tools). In
addition, tools with different names but essentially the
same meaning were merged (e.g., Borg Dyspnea Index and
Borg Index; escalation of therapy and change in therapy;
WHO class I, IIa, IIb, IIIa, IIIb, IV and WHO functional
class).
RESULTS
Response rate and characterization of participants. Of
200 invited PAH-SSc experts, 87 (43.5%) participated in
stage 1 of the Delphi exercise. Seventy-eight experts par-
ticipated in stage 2, 75 in stage 3, and 69 completed all 3
stages.
Among the 69 participants responding in all 3 Delphi
stages, 34 (49%) were rheumatologists, 1 was a dermatol-
ogist, and 34 (49%) were cardiologists or pulmonologists.
Sixty experts (64%) were located in North America, 28
(32%) were from Europe, 1 was from Asia, and 1 was from
Australia. The majority worked at academic institutions
(94%) and saw 6 patients with SSc per month (80%).
Domains and tools after Delphi stages 1 and 2. In stage
1 of the Delphi survey, 17 domains and 86 measurement
tools were rated by the participants (Figure 1). The do-
mains consisted of biomarkers, cardiac function, discon-
tinuation of treatment, dyspnea, exercise testing, fatigue,
WHO/NYHA functional class, global state as assessed by
physician, global state as assessed by patient, heart imag-
ing, lung parenchymal, lung vascular, miscellaneous
symptoms, participation/social activities, pulmonary arte-
rial pressure, quality of life/activities of daily living, and
utilities. Seventy-three additional tools, but no additional
domains, were suggested by the respondent group in Del-
phi stage 1. Thus, in stage 2, 17 domains and 159 tools
were rated.
After stage 2, a cluster analysis was performed to reduce
the high number of domains and tools in a rational manner
based on the ratings by the respondent group. The do-
mains fatigue, miscellaneous symptoms, participation,
and utilities were grouped in the lower cluster (less im-
portant/appropriate) and were therefore removed from fur-
ther evaluation. We kept the domain biomarkers (even
though it was in the lower cluster) because it contained
tools from the upper cluster that could not reasonably be
moved to another domain. In addition, we created a new
domain, health economics, to summarize tools not logi-
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cally combined in any other way. Finally, the domains
lung vascular and pulmonary arterial pressure were
pooled because they reflected the same measurement
tools. Overall, cluster analysis reduced the EPOSS instru-
ment to 12 domains containing 44 tools after stage 2 of the
Delphi survey.
Results of Delphi stage 3. The overall goal of the Delphi
survey was to define a core set of outcome measures to use
in randomized controlled trials in PAH-SSc. For practical
means, the number of domains and tools had to be further
reduced by repeating the cluster analysis after Delphi stage
3. The distribution of the ratings after stage 3 of the Delphi
survey is shown in Figure 2. In this second cluster analy-
sis, 4 domains were categorized in the cluster of lower
importance (Table 1): WHO/NYHA functional class, global
state as assessed by the patient, biomarkers, and health
economics. The following 8 domains were categorized in
the cluster of high importance: lung vascular/pulmonary
arterial pressure, exercise testing, cardiac function, dys-
pnea, discontinuation of treatment, quality of life, lung
parenchymal, and global state as assessed by the physi-
cian. Thus, these 8 domains were considered by the ex-
perts as most appropriate and important for PAH-SSc.
The ratings for the individual tools by cluster analysis
are shown in Figure 3. The tools in the upper cluster of
high importance were survival, right heart catheter, (seri-
ous) adverse events, 6-minute walk test, pulmonary func-
tion tests, oxygen saturation, high-resolution computed
tomography, echocardiography, cardiac right ventricular
Figure 2. Ratings of domains after Delphi stage 3 (5  very appropriate and 1  very
inappropriate for use in a combined end point in a randomized clinical trial). Of the 12
domains that were rated at stage 3, 8 were in the upper cluster and 4 in the lower cluster.
WHO  World Health Organization; NYHA  New York Heart Association.
Table 1. Results of the cluster analysis (domains and number of corresponding tools)
after stage 3*
Cluster of
tools
No. of
tools1 2
Cluster of domains
1
Cardiac function 3 5 8
Discontinuation of treatment 2 2
Dyspnea 1 1 2
Exercise testing 2 2
Global state as assessed by the physician 1 7 8
Lung parenchymal 2 1 3
Lung vascular (including pulmonary arterial pressure) 2 3 5
Quality of life/activities of daily living 2 2
2
Biomarkers 1 1
WHO/NYHA functional class 2 2
Global state as assessed by the patient 4 4
Health economics 5 5
No. of tools 13 31 44
* WHO  World Health Organization; NYHA  New York Heart Association.
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function with pulmonary capillary wedge pressure, and
severity of dyspnea. Note that some domains in the upper
cluster did not include tools in the upper cluster (e.g.,
quality of life) (Figure 4).
Final core set of domains and tools. An overview of the
distribution of domains and tools after the cluster analysis
is provided in Table 1. For the final core set of outcome
measures for clinical trials, the steering committee made
the following adjustments, based on clinical consider-
ations. Because the upper cluster domain quality of life/
activities of daily living did not contain tools in the upper
cluster, we included the tools Short Form 36 (SF-36) and
Health Assessment Questionnaire disability index for the
final core set. Although these tools were in the lower tools
cluster, they are validated and tools were required to mea-
sure quality of life. In the domain, cardiac function, the
tool cardiac right ventricular function with pulmonary
capillary wedge pressure was merged with right heart
catheterization because they reflected the same measure-
ment tool and because capillary wedge pressure is used for
the differential diagnosis rather than as a followup mea-
sure. Finally, the domain lung parenchymal and its mea-
Figure 3. Ratings of tools after Delphi stage 3 (multiple assigned tools are shown with
superordinate domains in square brackets; 5  very appropriate and 1  very inappropriate
for use in a combined end point in a randomized clinical trial). Of the 44 tools that were
rated at stage 3, 13 were in the upper cluster and 31 in the lower cluster. PAP  pulmonary
arterial pressure; PCWP  pulmocapillary wedge pressure; VAS  visual analog scale;
SF-36  Short Form 36; WHO  World Health Organization; HAQ  Health Assessment
Questionnaire; CT  computed tomography.
Figure 4. Summary of domains and tools after Delphi stage 3 (5
very appropriate and 1 very inappropriate for use in a combined
end point in a randomized clinical trial). Domains are shown in
bold and measurement tools in nonbold. PCWP  pulmocapillary
wedge pressure; VAS  visual analog scale.
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surement tools were removed from the final core set be-
cause this domain is usually used for the differential
diagnosis of pulmonary hypertension related to interstitial
fibrosis and therefore does not represent an appropriate
outcome measure for PAH in clinical trials.
Taken together, the following core set measures were
judged by the experts as the most appropriate and com-
prehensive measures to use in randomized controlled tri-
als in PAH-SSc (Table 2): lung vascular/pulmonary arterial
pressure as analyzed by right heart catheterization and
echocardiography, exercise testing as measured by the
6-minute walking test and oxygen saturation before/dur-
ing/after exercise, cardiac function as measured by right
heart catheterization and echocardiography, severity of
dyspnea as measured on a visual analog scale, discontin-
uation of treatment as measured by serious adverse events
and adverse events, quality of life/activities of daily living
as measured by the SF-36 score and Health Assessment
Questionnaire disability index, and global state assessed
by the physician as measured by survival. There remained
a large number of tools and a few domains from the lower
cluster in stages 2 and 3, which were considered as re-
search items and, if found valid and useful by future
research, can potentially be added to the results of the
present Delphi.
DISCUSSION
The primary purpose of this report is to describe the pro-
cess and results of a Delphi survey to develop a core set to
be used in clinical trials and validated specifically in PAH-
SSc. This is the largest interdisciplinary study on outcome
measures in PAH-SSc and complements the methodologic
work conducted by the PAH guideline groups, rheumato-
logic groups, and the OMERACT groups (2,17,19,30).
When interpreting the outcomes of this exercise, certain
methodologic considerations should be taken into ac-
count. We applied the usual elements of the Delphi tech-
nique, including a structured flow of information, feed-
back to the participants, and anonymity for the
participants during the exercise itself (thus not inhibiting
their input). Many Delphi exercises utilize a small number
of experts and sometimes also include face-to-face meet-
ings (31,32). In the present exercise, the Internet was used
exclusively, thus allowing a larger number of participants
to be included. It was also relatively cost efficient, because
no face-to-face meeting was necessary, thus avoiding
travel costs, loss of time, etc. The response rate we
achieved was somewhat lower than in previous published
exercises, probably owing to the fact that not all partici-
pants could be addressed personally or were not members
of predefined expert groups (31–33).
In addition, we chose to apply a statistical procedure
(cluster analysis) to differentiate between domains and
measurement tools of higher and lower importance. This
technique statistically separated groups and might have
resulted in 3 statistically separable groups. In fact, the
statistical procedure differentiated the domains and mea-
surement tools into 2 clusters (higher and lower impor-
tance). This procedure is useful because it decreases bi-
ases. In contrast, this procedure did require some
application of common sense and logic. For example, the
quality of life/activities of daily living domain, although
thought to be appropriate and a statistically high-impor-
tance domain, did not include any measurement tools.
Therefore, logic dictated that measurement tools such as
the SF-36 and Health Assessment Questionnaire disability
index be included in this domain. For consistency, some
measurement tools or domains were condensed. For ex-
ample, the tools for the lung vascular and pulmonary
arterial pressure domains were precisely the same so that
the domains were condensed into a single domain: lung
vascular/pulmonary arterial pressure.
Domains are groupings of highly related features that
describe an organ, disease, function, or physiology (e.g.,
cardiac function, pulmonary function, and quality of life)
and tools are specific measures for the domain. If no do-
mains are defined and only tools are rated, there is the
danger that a certain aspect of the disease (domain) is not
considered important simply because the appropriate
tools are not well known or not regularly used in daily
clinical practice. For instance, some physicians consid-
ered specific questionnaires (tools) as not very important,
while the majority agreed that quality of life is an impor-
tant domain. To avoid the possibility that such specific
aspects of the disease are not considered in the final core
set, domains and tools were separated. In contrast, the
assignment of tools to domains is sometimes not clear cut.
For instance, from the final core set of this exercise, sur-
vival could be considered its own domain, but could also
be a tool in the domain global state assessed by the phy-
sician because the cause of death due to PAH needs to be
verified by a physician.
One strength of the current study was the inclusion of
experts from different specialties for the Delphi survey.
This reflects the routine clinical care of these patients,
where experts from rheumatology, cardiology, and pul-
monology are required to cover the various clinical aspects
of PAH-SSc. Conversely, it is possible that some inconsis-
tencies were related to the multidisciplinary nature of this
Delphi exercise. For instance, not all of the respondents
were equally expert in using all of the measurement tools.
For example, rheumatologists, although knowledgeable,
would not perform right heart catheterizations whereas
Table 2. Final core set of domains and measurement
tools defined by the Delphi survey*
Domain Measurement tools
Lung vascular Right heart catheter, echocardiography
Exercise testing 6MWD, oxygen saturation at exercise
Cardiac function Right heart catheter, echocardiography
Dyspnea Dyspnea VAS
Discontinuation
of treatment
Adverse events, serious adverse events
Quality of life SF-36, HAQ DI
Global state by
physician
Survival
* 6MWD  6-minute walking distance; VAS  visual analog scale;
SF-36  Short Form 36 score; HAQ DI  Health Assessment Ques-
tionnaire disability index.
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cardiologists and pulmonologists would not be as expert
as rheumatologists in quality of life/activities of daily liv-
ing instruments. Although our procedures asked partici-
pants not to rate tools in which they were not expert, this
aspect could not be verified.
It must be emphasized that the final core set of outcome
measures of this Delphi survey is the subjective opinion of
experts in the field. This should not be confused with
validation of particular domains and measurement tools,
which was not the aim of the present study. As an exam-
ple, right heart catheterization has high face, content, and
criterion validity, whereas the 6-minute walking test lacks
several aspects of validation in patients with SSc. There-
fore, the final core set defined by this Delphi survey can be
seen as a priority list for domains and measurement tools
for which a full validation should be achieved first in the
following years. In these validation studies, it will also be
assessed whether the proposed core set of outcome mea-
sures covers the confounding factors and comorbidities of
PAH-SSc. The EPOSS group is currently (November 2007)
performing a systematic literature review to analyze which
aspects of validation are missing in the core set recom-
mended in this article. The missing aspects of validation
will then be addressed as a research agenda in future
studies. This does not mean that domains and measure-
ment tools not included in the final core set cannot qualify
as appropriate outcome measures for PAH-SSc in the fu-
ture. As an example, biomarkers such as pro–brain natri-
uretic peptide might be considered a research tool for
PAH-SSc by experts at the current time, but might become
a valid outcome measure after further studies have been
conducted and published. The current study also did not
differentiate between surrogate end points (defined as
measurement tools that substitute for a meaningful end
point such as survival) and intermediate end points (de-
fined as measurement tools that reflect how a patient feels
without necessarily fully substituting the meaningful end
point such as survival).
Taken together, this multidisciplinary Delphi survey de-
fined a core set of outcome measures for clinical trials in
PAH-SSc on a statistical basis modified by logical and
medical rationale. Measurement tools in the final core set
included lung physiology, right heart catheterization,
echocardiography, 6-minute walking test, oxygen satura-
tion before/during/after exercise, severity of dyspnea mea-
sured on a visual analog scale, (serious) adverse events, the
SF-36 score, the Health Assessment Questionnaire disabil-
ity index, and survival. Although these measurement tools
are recommended by this group to be used at this time, it
will be necessary to formally validate the present mea-
sures, as well as the potential research measures, accord-
ing to a procedure such as the OMERACT filter.
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